Thursday, April, 18, 2019 08:36:48

Category: Pharmaceuticals

Dr. Reddy’s Laboratories acquires 42 ANDAs portfolio in the U.S.

The portfolio in question includes over 30 generic injectable products.  The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …

GlaxoSmithKline Plc receives U.S FDA approval for HIV drug Dovato

One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …

Aeglea presents positive data for Pegzilarginase to treat ARG1-D

The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …

Viking Therapeutics to present data from Phase 2 study of VK2809

Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …

Neon Therapeutics unveils new data in clinical trial of cancer vaccine

The study will evaluate the combination of NEO-PV-01 with nivolumab (anti-PD-1 therapy) in metastatic or advanced melanoma patients Neon Therapeutics Inc., an immuno-oncology company which develops neoantigen-based treatments has reportedly presented updated data that describes pathologic and immune markers related with durable clinical advantages in …

Theravance’s Ampreloxetine clinical data to be presented at 32nd ENC

The clinical data would be coming from the company’s phase-2 ampreloxetine clinical trials. The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy. Theravance Biopharma, Inc., (Theravance Biopharma), a renowned diversified biopharmaceutical company, has reportedly announced the outcome of the …